XML 36 R22.htm IDEA: XBRL DOCUMENT v3.25.3
LICENSE REVENUES (Tables)
 9 Months Ended
Sep. 30, 2025
Collaborative Arrangement and Arrangement Other than Collaborative [Abstract]  
Schedule of License and Grant Revenue
The following table summarizes the total revenue recorded in the Company’s condensed consolidated statements of operations (in thousands) during the nine months ended September 30, 2025 and September 30, 2024:
NINE MONTHS ENDED
SEPTEMBER 30,
20252024
License fee revenue
Scithera, Inc.$1,300 $— 
Regeneron Pharmaceuticals, Inc.— 100 
Total license fee revenue$1,300 $100